Inhibrx Biosciences, Inc.

Expand Phase 2 trial to include 50 additional HPV-positive HNSCC patients

Deadline not yet reached (886 days left)

Announced: 8 Sep 2026
Due: 31 Mar 2029

Deadline
Met
Late
Not met
Today

What the company said

“Expansion of Phase 2 to include 50 additional HPV+ patients may serve as potential path to accelerated approval by end of '28/early '29”

SourceInhibrx Biosciences, Inc. Form 8-K press release, 2026-09-08
FilingSEC filing index
Deadline as statedby end of '28/early '29
Deadline used31 Mar 2029, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-INBX-000439
Cite as https://keptindex.org/c/KI-C-2026-INBX-000439/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2029.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Rollout
Indicative materiality: Low rules
Action: Expand

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Inhibrx Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-INBX-000439 · Corrections policy